-
1
-
-
84979705347
-
-
Atlanta, GA: CDC, ; (accessed on 15 June 2016)
-
Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Atlanta, GA: CDC, 2016; Available at http://www.cdc.gov/drugresistance/threat-report-2013/ (accessed on 15 June 2016).
-
(2016)
Antibiotic Resistance Threats in the United States, 2013
-
-
-
2
-
-
10944272743
-
Antibacterial resistance worldwide: Causes, challenges and responses
-
Dec.
-
Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 2004 Dec; 10(12 Suppl): S122-S129.
-
(2004)
Nat Med
, vol.10
, Issue.12
, pp. S122-S129
-
-
Levy, S.B.1
Marshall, B.2
-
3
-
-
72849135301
-
Antimicrobial susceptibility testing: A review of general principles and contemporary practices
-
Jorgensen JH, Ferraro MJ. Antimicrobial susceptibility testing: a review of general principles and contemporary practices. Clin Infect Dis 2009; 149: 1749-1755.
-
(2009)
Clin Infect Dis
, vol.149
, pp. 1749-1755
-
-
Jorgensen, J.H.1
Ferraro, M.J.2
-
4
-
-
84875261410
-
Combination approaches to combat multidrug-resistant bacteria
-
Mar.
-
Worthington RJ, Melander C. Combination approaches to combat multidrug-resistant bacteria. Trends Biotechnol 2013 Mar; 31: 177-184.
-
(2013)
Trends Biotechnol
, vol.31
, pp. 177-184
-
-
Worthington, R.J.1
Melander, C.2
-
5
-
-
84911003547
-
Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: A systematic review
-
Poulikakos P, Tansarli GS, Falagas ME. Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review. Eur J Clin Microbiol Infect Dis 2014; 33: 1675-1685.
-
(2014)
Eur J Clin Microbiol Infect Dis
, vol.33
, pp. 1675-1685
-
-
Poulikakos, P.1
Tansarli, G.S.2
Falagas, M.E.3
-
6
-
-
84926343938
-
Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: A retrospective cohort study
-
Zilberberg MD, Shorr AF, Micek ST, Vazquez-Guillamet C, Kollef MH. Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study. Crit Care 2014; 18: 6.
-
(2014)
Crit Care
, vol.18
, pp. 6
-
-
Zilberberg, M.D.1
Shorr, A.F.2
Micek, S.T.3
Vazquez-Guillamet, C.4
Kollef, M.H.5
-
7
-
-
84983591272
-
Verification of an automated, digital dispensing platform for at-will broth microdilution antimicrobial susceptibility testing
-
Smith KP, Kirby JE. Verification of an automated, digital dispensing platform for at-will broth microdilution antimicrobial susceptibility testing. J Clin Microbiol 2016; 54: 2288-2293.
-
(2016)
J Clin Microbiol
, vol.54
, pp. 2288-2293
-
-
Smith, K.P.1
Kirby, J.E.2
-
8
-
-
84921048160
-
The impact of hospital-acquired infections with multidrug-resistant bacteria in an oncology intensive care unit
-
Cornejo-Juarez P, Vilar-Compte D, Perez-Jimenez C, Namendys-Silva SA, Sandoval-Hernandez S, Volkow-Fernandez P. The impact of hospital-acquired infections with multidrug-resistant bacteria in an oncology intensive care unit. Int J Infect Dis 2015; 31: 31-34.
-
(2015)
Int J Infect Dis
, vol.31
, pp. 31-34
-
-
Cornejo-Juarez, P.1
Vilar-Compte, D.2
Perez-Jimenez, C.3
Namendys-Silva, S.A.4
Sandoval-Hernandez, S.5
Volkow-Fernandez, P.6
-
9
-
-
34249901630
-
Timing of adequate antibiotic therapy is a greater determinant of outcome than are TNF and IL-10 polymorphisms in patients with sepsis
-
Garnacho-Montero J, Aldabo-Pallas T, Garnacho-Montero C et al. Timing of adequate antibiotic therapy is a greater determinant of outcome than are TNF and IL-10 polymorphisms in patients with sepsis. Crit Care 2006; 10: R111.
-
(2006)
Crit Care
, vol.10
, pp. R111
-
-
Garnacho-Montero, J.1
Aldabo-Pallas, T.2
Garnacho-Montero, C.3
-
10
-
-
84948709890
-
Antibiotic resistance breakers: Can repurposed drugs fill the antibiotic discovery void?
-
Brown D. Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void? Nat Rev Drug Discov 2015; 14: 821-832.
-
(2015)
Nat Rev Drug Discov
, vol.14
, pp. 821-832
-
-
Brown, D.1
-
11
-
-
16644367566
-
Antimicrobial drug development - The past, the present, and the future
-
Powers JH. Antimicrobial drug development - the past, the present, and the future. Clin Microbiol Infec 2004; 10: 23-31.
-
(2004)
Clin Microbiol Infec
, vol.10
, pp. 23-31
-
-
Powers, J.H.1
-
12
-
-
84865574615
-
Repurposing screens identify rifamycins as potential broad-spectrum therapy for multidrug-resistant Acinetobacter baumannii and select agent microorganisms
-
Chromy BA, Elsheikh M, Christensen TL et al. Repurposing screens identify rifamycins as potential broad-spectrum therapy for multidrug-resistant Acinetobacter baumannii and select agent microorganisms. Future Microbiol 2012; 7: 1011-1020.
-
(2012)
Future Microbiol
, vol.7
, pp. 1011-1020
-
-
Chromy, B.A.1
Elsheikh, M.2
Christensen, T.L.3
-
13
-
-
84903757348
-
Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library
-
Feng J, Wang T, Shi WL et al. Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library. Emerg Microbes Infect 2014; 3: e49.
-
(2014)
Emerg Microbes Infect
, vol.3
, pp. e49
-
-
Feng, J.1
Wang, T.2
Shi, W.L.3
-
14
-
-
84928920149
-
Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis
-
Harbut MB, Vilcheze C, Luo X et al. Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis. Proc Natl Acad Sci USA 2015; 7112: 4453-4458.
-
(2015)
Proc Natl Acad Sci USA
, vol.7112
, pp. 4453-4458
-
-
Harbut, M.B.1
Vilcheze, C.2
Luo, X.3
-
15
-
-
84985947120
-
Progress in the fight against multidrug-resistant bacteria? A review of U.S. Food and drug administration-approved antibiotics, 2010-2015
-
Deak D, Outterson K, Powers JH, Kesselheim AS. Progress in the fight against multidrug-resistant bacteria? A review of U.S. Food and Drug Administration-approved antibiotics, 2010-2015. Ann Intern Med 2016; 165: 363-372.
-
(2016)
Ann Intern Med
, vol.165
, pp. 363-372
-
-
Deak, D.1
Outterson, K.2
Powers, J.H.3
Kesselheim, A.S.4
-
16
-
-
79955428497
-
The NCGC pharmaceutical collection: A comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics
-
Huang RL, Southall N, Wang YH et al. The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med 2011; 3: 80ps16.
-
(2011)
Sci Transl Med
, vol.3
, pp. 80ps16
-
-
Huang, R.L.1
Southall, N.2
Wang, Y.H.3
-
17
-
-
77950397958
-
Lateral patch-clamping in a standard 1536-well microplate format
-
Tang KC, Reboud J, Kwok YL, Peng SL, Yobas L. Lateral patch-clamping in a standard 1536-well microplate format. Lab Chip 2010; 10: 1044-1050.
-
(2010)
Lab Chip
, vol.10
, pp. 1044-1050
-
-
Tang, K.C.1
Reboud, J.2
Kwok, Y.L.3
Peng, S.L.4
Yobas, L.5
-
18
-
-
67649997684
-
Microfractionation revisited: A 1536 well high resolution screening assay
-
Giera M, Heus F, Janssen L, Kool J, Lingeman H, Irth H. Microfractionation revisited: a 1536 well high resolution screening assay. Anal Chem 2009; 181: 5460-5466.
-
(2009)
Anal Chem
, vol.181
, pp. 5460-5466
-
-
Giera, M.1
Heus, F.2
Janssen, L.3
Kool, J.4
Lingeman, H.5
Irth, H.6
-
19
-
-
84943756669
-
Cell-based high-throughput screening for aromatase inhibitors in the Tox21 10 K library
-
Chen S, Hsieh JH, Huang R et al. Cell-based high-throughput screening for aromatase inhibitors in the Tox21 10 K library. Toxicol Sci 2015; 147: 446-457.
-
(2015)
Toxicol Sci
, vol.147
, pp. 446-457
-
-
Chen, S.1
Hsieh, J.H.2
Huang, R.3
-
20
-
-
33746789921
-
Quantitative high-throughput screening: A titrationbased approach that efficiently identifies biological activities in large chemical libraries
-
Inglese J, Auld DS, Jadhav A et al. Quantitative high-throughput screening: a titrationbased approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci USA 2006; 1103: 11473-11478.
-
(2006)
Proc Natl Acad Sci USA
, vol.1103
, pp. 11473-11478
-
-
Inglese, J.1
Auld, D.S.2
Jadhav, A.3
-
21
-
-
84979609071
-
Horizontal transfer of carbapenemase-encoding plasmids and comparison with hospital epidemiology data
-
Hardiman CA, Weingarten RA, Conlan S et al. Horizontal transfer of carbapenemase-encoding plasmids and comparison with hospital epidemiology data. Antimicrob Agents Chemother 2016; 60: 4910-4919.
-
(2016)
Antimicrob Agents Chemother
, vol.60
, pp. 4910-4919
-
-
Hardiman, C.A.1
Weingarten, R.A.2
Conlan, S.3
-
22
-
-
79955428497
-
The NCGC pharmaceutical collection: A comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics
-
Huang R, Southall N, Wang Y et al. The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med 2011; 3: 80ps16.
-
(2011)
Sci Transl Med
, vol.3
, pp. 80ps16
-
-
Huang, R.1
Southall, N.2
Wang, Y.3
-
23
-
-
84906754009
-
Chemical signatures and new drug targets for gametocytocidal drug development
-
Sun W, Tanaka TQ, Magle CT et al. Chemical signatures and new drug targets for gametocytocidal drug development. Sci Rep 2014; 4: 3743.
-
(2014)
Sci Rep
, vol.4
, pp. 3743
-
-
Sun, W.1
Tanaka, T.Q.2
Magle, C.T.3
-
25
-
-
84902211438
-
A new bliss independence model to analyze drug combination data
-
Zhao W, Sachsenmeier K, Zhang LJ, Sult E, Hollingsworth RE, Yang H. A new bliss independence model to analyze drug combination data. J Biomol Screen 2014; 19: 817-821.
-
(2014)
J Biomol Screen
, vol.19
, pp. 817-821
-
-
Zhao, W.1
Sachsenmeier, K.2
Zhang, L.J.3
Sult, E.4
Hollingsworth, R.E.5
Yang, H.6
-
26
-
-
84882667253
-
Rapid identification of antifungal compounds against Exserohilum rostratum using high throughput drug repurposing screens
-
Sun W, Park YD, Sugui JA et al. Rapid identification of antifungal compounds against Exserohilum rostratum using high throughput drug repurposing screens. Plos ONE 2013; 8: e70506.
-
(2013)
Plos ONE
, vol.8
, pp. e70506
-
-
Sun, W.1
Park, Y.D.2
Sugui, J.A.3
-
27
-
-
69249213919
-
A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-A-go-go-related gene channel
-
Titus SA, Beacham D, Shahane SA et al. A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel. Anal Biochem 2009; 1394: 30-38.
-
(2009)
Anal Biochem
, vol.1394
, pp. 30-38
-
-
Titus, S.A.1
Beacham, D.2
Shahane, S.A.3
-
28
-
-
0033047893
-
Oxidant mechanisms in gentamicin nephrotoxicity
-
Walker PD, Barri Y, Shah SV. Oxidant mechanisms in gentamicin nephrotoxicity. Ren Fail 1999; 21: 433-442.
-
(1999)
Ren Fail
, vol.21
, pp. 433-442
-
-
Walker, P.D.1
Barri, Y.2
Shah, S.V.3
-
30
-
-
84954287879
-
Auranofin efficacy against MDR Streptococcus pneumoniae and Staphylococcus aureus infections
-
Aguinagalde L, Diez-Martinez R, Yuste J et al. Auranofin efficacy against MDR Streptococcus pneumoniae and Staphylococcus aureus infections. J Antimicrob Chemother 2015; 70: 2608-2617.
-
(2015)
J Antimicrob Chemother
, vol.70
, pp. 2608-2617
-
-
Aguinagalde, L.1
Diez-Martinez, R.2
Yuste, J.3
-
31
-
-
84882598507
-
Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: A breakpoint artefact?
-
Schon T, Jureen P, Chryssanthou E et al. Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint artefact? J Antimicrob Chemother 2013; 68: 2074-2077.
-
(2013)
J Antimicrob Chemother
, vol.68
, pp. 2074-2077
-
-
Schon, T.1
Jureen, P.2
Chryssanthou, E.3
-
32
-
-
84927644630
-
Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection
-
He S, Lin B, Chu V et al. Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. Sci Transl Med 2015; 7: 282ra249.
-
(2015)
Sci Transl Med
, vol.7
, pp. 282ra249
-
-
He, S.1
Lin, B.2
Chu, V.3
-
33
-
-
0001707601
-
3′-Azido-3′-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro
-
Mitsuya H, Weinhold KJ, Furman PA et al. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 1985; 82: 7096-7100.
-
(1985)
Proc Natl Acad Sci USA
, vol.82
, pp. 7096-7100
-
-
Mitsuya, H.1
Weinhold, K.J.2
Furman, P.A.3
-
34
-
-
84908399993
-
Supergenomic network compression and the discovery of EXP1 as a glutathione transferase inhibited by artesunate
-
Lisewski AM, Quiros JP, Ng CL et al. Supergenomic network compression and the discovery of EXP1 as a glutathione transferase inhibited by artesunate. Cell 2014; 158: 916-928.
-
(2014)
Cell
, vol.158
, pp. 916-928
-
-
Lisewski, A.M.1
Quiros, J.P.2
Ng, C.L.3
-
35
-
-
0038147060
-
Gold compound auranofin inhibits IkappaB kinase (IKK) by modifying Cys-179 of IKKbeta subunit
-
Jeon KI, Byun MS, Jue DM. Gold compound auranofin inhibits IkappaB kinase (IKK) by modifying Cys-179 of IKKbeta subunit. Exp Mol Med 2003; 35: 61-66.
-
(2003)
Exp Mol Med
, vol.35
, pp. 61-66
-
-
Jeon, K.I.1
Byun, M.S.2
Jue, D.M.3
-
36
-
-
0039798749
-
Light-dependent volume changes and reactions in chloroplasts. I. Action of alkenylsuccinic acids and phenylmercuric acetate and possible relation to mechanisms of stomatal control
-
Siegenthaler PA, Packer L. Light-dependent volume changes and reactions in chloroplasts. I. Action of alkenylsuccinic acids and phenylmercuric acetate and possible relation to mechanisms of stomatal control. Plant Physiol 1965; 40: 785-791.
-
(1965)
Plant Physiol
, vol.40
, pp. 785-791
-
-
Siegenthaler, P.A.1
Packer, L.2
-
37
-
-
80052843743
-
The antifungal mechanism of action of zinc pyrithione
-
Reeder NL, Xu J, Youngquist RS, Schwartz JR, Rust RC, Saunders CW. The antifungal mechanism of action of zinc pyrithione. Br J Dermatol 2011; 165(Suppl 2): 9-12.
-
(2011)
Br J Dermatol
, vol.165
, pp. 9-12
-
-
Reeder, N.L.1
Xu, J.2
Youngquist, R.S.3
Schwartz, J.R.4
Rust, R.C.5
Saunders, C.W.6
-
39
-
-
0016242923
-
Antimicrobial actions of hexachlorophene: Inhibition of respiration in Bacillus megaterium
-
Frederick JJ, Corner TR, Gerhardt P. Antimicrobial actions of hexachlorophene: inhibition of respiration in Bacillus megaterium. Antimicrob Agents Chemother 1974; 6: 712-721.
-
(1974)
Antimicrob Agents Chemother
, vol.6
, pp. 712-721
-
-
Frederick, J.J.1
Corner, T.R.2
Gerhardt, P.3
-
40
-
-
0017815548
-
Tetracyclines: New look at old antibiotic. I. Clinical pharmacology, mechanism of action, and untoward effects
-
Siegel D. Tetracyclines: new look at old antibiotic. I. Clinical pharmacology, mechanism of action, and untoward effects. NY State J Med 1978; 78: 950-956.
-
(1978)
NY State J Med
, vol.78
, pp. 950-956
-
-
Siegel, D.1
-
41
-
-
84858627056
-
Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: Superiority of combination antimicrobial regimens
-
Qureshi ZA, Paterson DL, Potoski BA et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012; 56: 2108-2113.
-
(2012)
Antimicrob Agents Chemother
, vol.56
, pp. 2108-2113
-
-
Qureshi, Z.A.1
Paterson, D.L.2
Potoski, B.A.3
-
42
-
-
77949569493
-
Antibiotic resistance and its cost: Is it possible to reverse resistance?
-
Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 2010; 8: 260-271.
-
(2010)
Nat Rev Microbiol
, vol.8
, pp. 260-271
-
-
Andersson, D.I.1
Hughes, D.2
-
43
-
-
84971672804
-
Drug combination therapy increases successful drug repositioning
-
Sun W, Sanderson P, Zheng W. Drug combination therapy increases successful drug repositioning. Drug Discov Today 2016; 21: 1189-1195.
-
(2016)
Drug Discov Today
, vol.21
, pp. 1189-1195
-
-
Sun, W.1
Sanderson, P.2
Zheng, W.3
-
44
-
-
84925498076
-
Auranofin: Repurposing an old drug for a golden new age
-
Roder C, Thomson MJ. Auranofin: repurposing an old drug for a golden new age. Drugs R D 2015; 15: 13-20.
-
(2015)
Drugs R D
, vol.15
, pp. 13-20
-
-
Roder, C.1
Thomson, M.J.2
-
45
-
-
84979021154
-
Rifabutin: Where do we stand in 2016?
-
Crabol Y, Catherinot E, Veziris N, Jullien V, Lortholary O. Rifabutin: where do we stand in 2016? J Antimicrob Chemother 2016; 71: 1759-1771.
-
(2016)
J Antimicrob Chemother
, vol.71
, pp. 1759-1771
-
-
Crabol, Y.1
Catherinot, E.2
Veziris, N.3
Jullien, V.4
Lortholary, O.5
-
46
-
-
84880379313
-
Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: A multicenter, randomized clinical trial
-
Durante-Mangoni E, Signoriello G, Andini R et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clinical Infectious Diseases 2013; 57: 349-358.
-
(2013)
Clinical Infectious Diseases
, vol.57
, pp. 349-358
-
-
Durante-Mangoni, E.1
Signoriello, G.2
Andini, R.3
-
47
-
-
84910127305
-
When does 2 plus 2 equal 5? A review of antimicrobial synergy testing
-
Doern CD. When does 2 plus 2 equal 5? a review of antimicrobial synergy testing. J Clin Microbiol 2014; 52: 4124-4128.
-
(2014)
J Clin Microbiol
, vol.52
, pp. 4124-4128
-
-
Doern, C.D.1
-
48
-
-
23444457294
-
Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: A randomised, double-blind, controlled clinical trial
-
Aaron SD, Vandemheen KL, Ferris W et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 2005; 366: 463-471.
-
(2005)
Lancet
, vol.366
, pp. 463-471
-
-
Aaron, S.D.1
Vandemheen, K.L.2
Ferris, W.3
-
49
-
-
34548833833
-
Antibiotic synergy testing should not be routine for patients with cystic fibrosis who are infected with multiresistant bacterial organisms
-
Aaron SD. Antibiotic synergy testing should not be routine for patients with cystic fibrosis who are infected with multiresistant bacterial organisms. Paediatr Respir Rev 2007; 8: 256-261.
-
(2007)
Paediatr Respir Rev
, vol.8
, pp. 256-261
-
-
Aaron, S.D.1
-
50
-
-
84971277787
-
Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): A study protocol
-
Dickstein Y, Leibovici L, Yahav D et al. Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol. BMJ Open 2016; 6: e009956.
-
(2016)
BMJ Open
, vol.6
, pp. e009956
-
-
Dickstein, Y.1
Leibovici, L.2
Yahav, D.3
-
51
-
-
79952419254
-
Methodological and practical challenges for personalized cancer therapies
-
Wistuba II, Gelovani JG, Jacoby JJ, Davis SE, Herbst RS. Methodological and practical challenges for personalized cancer therapies. Nat Rev Clin Oncol 2011; 8: 135-141.
-
(2011)
Nat Rev Clin Oncol
, vol.8
, pp. 135-141
-
-
Wistuba, I.I.1
Gelovani, J.G.2
Jacoby, J.J.3
Davis, S.E.4
Herbst, R.S.5
|